Bridging preclinical to commercial manufacturing in cell therapy: mind the gap

Ashwin Srinivasan Kumar, Sabry Hamza, Jaichandran Sivalingam

18 September 2025

Viewpoint

Avoiding slowdowns on the cell and gene therapy development pathway

William E Janssen, Scott R Burger

02 September 2025

Viewpoint

Cryopreservation of autologous patient material for onwards manufacture

Chris Leonforte

02 June 2025

Viewpoint

Investing in early-stage stem cell therapy developers

Stijn Heessen, Kristian Tryggvason

21 February 2025

Viewpoint

Autologous induced pluripotent stem cell (iPSC)-derived therapies: a realistic solution for advancing regenerative medicine

Jarett Anderson, Timothy Nelson

17 January 2024

Viewpoint

Following the (mAb) leader: leveraging monoclonal antibody cell line development & banking CMC strategies for iPSC-derived cell therapies

Damien Fink

17 January 2024

Viewpoint

Navigating the final mile: how are hospitals providing capabilities for commercial cell therapy product delivery?

Alexey Bersenev

29 November 2023

Viewpoint

Navigating the final mile: how are Australian hospitals delivering autologous cell & gene therapies?

Sharon Sagnella

10 November 2023

Viewpoint

Building resilience into post-pandemic cell & gene therapy supply chains

Tiffany Clement, Cheryl Cox

18 November 2022

Viewpoint

The living cell supply chain: a product-specific, rational approach to management of cellular starting material donors & donations

William E Janssen, Scott R. Burger

18 November 2022

Viewpoint

Pandemic-related supply chain disruptions in cell therapy require rapid qualification for single-sourced materials

John Duguid, Paul Friedman

07 March 2022

Viewpoint